First coeliac disease vaccine moves forward in expanded clinical programme
This article was originally published in Scrip
Some of the $20 million that the US startup ImmusanT raised late last year in a Series A financing is being put to use with the start of an expanded international clinical programme for Nexvax2, its ground-breaking therapeutic vaccine for coeliac disease.One of the new placebo-controlled Phase I trials will see around 84 patients enrolled across four sites in Australia and New Zealand, in which induction of tolerance in individuals on a gluten-free diet will be assessed at multiple ascending doses.
You may also be interested in...
Execs from Merck, Pfizer, Bristol, Abbvie and smaller biopharmas weigh in on how developments in cancer research may benefit other disease areas, especially autoimmune and neurological conditions.
Partners say they are encouraged by new overall response data from early trials for the two drugs together in kidney and liver cancer, presented to ASCO.
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.